Weidauer Stefan, Hattingen Elke
Institute of Neuroradiology, Goethe University, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany.
Biomedicines. 2025 Mar 1;13(3):603. doi: 10.3390/biomedicines13030603.
The prevalence of cerebral amyloid angiopathy (CAA) has been shown to increase with age, with rates reported to be around 50-60% in individuals over 80 years old who have cognitive impairment. The disease often presents as spontaneous lobar intracerebral hemorrhage (ICH), which carries a high risk of recurrence, along with transient focal neurologic episodes (TFNE) and progressive cognitive decline, potentially leading to Alzheimer's disease (AD). In addition to ICH, neuroradiologic findings of CAA include cortical and subcortical microbleeds (MB), cortical subarachnoid hemorrhage (cSAH) and cortical superficial siderosis (cSS). Non-hemorrhagic pathologies include dilated perivascular spaces in the centrum semiovale and multiple hyperintense lesions on T2-weighted magnetic resonance imaging (MRI). A definitive diagnosis of CAA still requires histological confirmation. The Boston criteria allow for the diagnosis of a probable or possible CAA by considering specific neurological and MRI findings. The recent version, 2.0, which includes additional non-hemorrhagic MRI findings, increases sensitivity while maintaining the same specificity. The characteristic MRI findings of autoantibody-related CAA-related inflammation (CAA-ri) are similar to the so-called "amyloid related imaging abnormalities" (ARIA) observed with amyloid antibody therapies, presenting in two variants: (a) vasogenic edema and leptomeningeal effusions (ARIA-E) and (b) hemorrhagic lesions (ARIA-H). Clinical and MRI findings enable the diagnosis of a probable or possible CAA-ri, with biopsy remaining the gold standard for confirmation. In contrast to spontaneous CAA-ri, only about 20% of patients treated with monoclonal antibodies who show proven ARIA on MRI also experience clinical symptoms, including headache, confusion, other psychopathological abnormalities, visual disturbances, nausea and vomiting. Recent findings indicate that treatment should be continued in cases of mild ARIA, with ongoing MRI and clinical monitoring. This review offers a concise update on CAA and its associated consequences.
脑淀粉样血管病(CAA)的患病率已被证明随年龄增长而增加,据报道,80岁以上有认知障碍的个体中,患病率约为50%-60%。该疾病常表现为自发性脑叶脑出血(ICH),其复发风险高,还伴有短暂性局灶性神经发作(TFNE)和进行性认知衰退,可能导致阿尔茨海默病(AD)。除ICH外,CAA的神经放射学表现还包括皮质和皮质下微出血(MB)、皮质蛛网膜下腔出血(cSAH)和皮质表面铁沉积(cSS)。非出血性病变包括半卵圆中心的血管周围间隙增宽和T2加权磁共振成像(MRI)上的多个高信号病变。CAA的明确诊断仍需组织学证实。波士顿标准通过考虑特定的神经学和MRI表现来诊断可能或疑似的CAA。最新版本2.0纳入了额外的非出血性MRI表现,在保持相同特异性的同时提高了敏感性。自身抗体相关的CAA相关炎症(CAA-ri)的特征性MRI表现与淀粉样抗体治疗中观察到的所谓“淀粉样相关成像异常”(ARIA)相似,有两种变体:(a)血管源性水肿和软脑膜积液(ARIA-E)和(b)出血性病变(ARIA-H)。临床和MRI表现有助于诊断可能或疑似的CAA-ri,活检仍是确诊的金标准。与自发性CAA-ri不同,在MRI上显示已证实的ARIA的单克隆抗体治疗患者中,只有约20%会出现临床症状,包括头痛、意识模糊、其他精神病理异常、视觉障碍、恶心和呕吐。最近的研究结果表明,对于轻度ARIA病例应继续治疗,并持续进行MRI和临床监测。本综述简要介绍了CAA及其相关后果的最新情况。